<?xml version="1.0" encoding="UTF-8"?>

<wo-patent-document lang="la" status="Filed" country="LA">
  <wo-bibliographic-data status="Formalities examination">
    <classifications-ipcr>
      <classification-ipcr sequence="0001">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>213</main-group>
        <subgroup>00</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0002">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>231</main-group>
        <subgroup>12</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0003">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>237</main-group>
        <subgroup>06</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0004">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>253</main-group>
        <subgroup>08</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
    </classifications-ipcr>
    <application-reference>
      <document-id>
        <country>LA</country>
        <doc-number>P/999</doc-number>
        <date>20250214</date>
      </document-id>
    </application-reference>
    <priority-claims>
      <priority-claim sequence="0001" kind="national">
        <country>EU</country>
        <doc-number>19169714.3</doc-number>
        <date>20190417</date>
      </priority-claim>
    </priority-claims>
    <parties>
      <applicants>
        <applicant sequence="0001" app-type="applicant" designation="all">
          <addressbook lang="la">
            <name>Newron Pharmaceuticals S.p.A</name>
            <address>
              <address-1>Via Antonio Meucci, 3, 20091 BRESSO, Italy</address-1>
              <country>IT</country>
            </address>
          </addressbook>
          <nationality>
            <country/>
          </nationality>
          <residence>
            <country>IT</country>
          </residence>
        </applicant>
      </applicants>
      <inventors>
        <inventor sequence="0001">
          <addressbook lang="la">
            <name>SKRANC, Wolfgang</name>
            <address>
              <address-1>Oberfeldgasse 23, 1220 WIEN, Austria</address-1>
              <country>AU</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0002">
          <addressbook lang="la">
            <name>WOLBERG, Michael</name>
            <address>
              <address-1>Herbert-Scholz-Str. 22, 9307 3 NEUTRAUBLING' Germany</address-1>
              <country>DE</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0003">
          <addressbook lang="la">
            <name>RIEPL, Matthias</name>
            <address>
              <address-1>Weinbergstrasse 3, 93177 ALTBNHANN, Germany</address-1>
              <country>DT</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0004">
          <addressbook lang="la">
            <name>IMBODEN, ChristoPh</name>
            <address>
              <address-1>Römerstrasse 12, 4114 HOFSTETTEN, SOLOTHURN, Switzerland</address-1>
              <country>CH</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0005">
          <addressbook lang="la">
            <name>WALDVOGEL, Erwin</name>
            <address>
              <address-1>Reinacherstrasse Post code): 18, 4147 AESCH, Switzerland</address-1>
              <country>SZ</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
      <agents>
        <agent sequence="0001" rep-type="agent">
          <addressbook lang="la">
            <name>CONCETTI-LAO CO., LTD</name>
            <address>
              <address-1>Lao-Thai Friendship Road, Sokpaluang Village,Sisattanak District, Vientiane Lao PDR</address-1>
              <country>LA</country>
            </address>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <invention-title lang="la">ຂະບວນການສໍາລັບການຜະລິດຂອງຖືກທົດແທນສານມາຈາກ 2-[2-(ເຟນີນ) ເອຕີນອາມີໂນ] ອານການອາມິດ</invention-title>
    <invention-title lang="en">"PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES"</invention-title>
    <wo-national-office-event national-office-event-type="Filed" doc-number="P/999" event-name="Filing">
      <wo-national-office-event-date>
        <date>20250214</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-filing-data appl-type="Patent - Foreign" file-type="">
      <kind-of-protection>Patent - Foreign</kind-of-protection>
    </wo-national-office-filing-data>
  </wo-bibliographic-data>
  <abstract lang="en">
    <p num="0001">&lt;p&gt;The&amp;nbsp;present invention relates to a new process for the production of substituted 2-12-(phenyl) ethylaminolalkaneamide derivatives of the following formula (I), in&lt;br /&gt; particdar2-12- (3-butoxyphenyl)-ethylaminol-N,N-dimethylacetamide in high yields with&lt;br /&gt; very high chemical purity. The invention relates to a process for preparing&lt;br /&gt; a compound of formula (I) or a 5 pharmaceutically acceptable salt thereof:&lt;/p&gt;</p>
  </abstract>
  <abstract lang="la">
    <p num="0002">&lt;p&gt;ການສະເໜີການຄົ້ນພົບ ພົວພັນເຖິງຂະບວນການໃໝ່ໝຶ່ງສໍາລັບການຜະລິດຂອງຖືກທົດແທນສານມາຈາກ 2-[2-(ເຟນີນ) ເອຕີນອາມີໂນ] ອານການອາມິດຂອງສູດແບບຕັ້ງຕໍ່ໄປນີ້ (I), ໂດຍສະເພາະ 2-[2-(3-ບູໂຕຊີເຟນີນ)-ເອຕີນອາມີໂນ]-N,N-ດີເມຕີນອາເຊຕາມິດ ໃນຜົນໄດ້ຮັບ ສູງດ້ວຍຄວາມບໍລິສຸດສານເຄມີສູງຫຼາຍ. ການຄົ້ນພົບພົວພັນເຖິງຂະບວນການໜຶ່ງສໍາລັບການປຸງແຕ່ງສ່ວນປະສົມໜຶ່ງຂອງສູດແບບດຕັ້ງ ຫຼື ການຢາໜຶ່ງທີ່ຍອມຮັບໄດ້ເກືອເຫຼົ່ານັ້ນ.&lt;/p&gt;</p>
  </abstract>
</wo-patent-document>
